Thioacetamide (TAA) undergoes bioactivation in the liver by the CYP450 2E1 enzyme,
resulting in the formation of TAA-S-oxide and TAA-S-dioxide. TAA-S-dioxide induces …

Valproic acid (VPA) is an anti-seizure drug that causes idiosyncratic liver injury. 2-propyl-4-
pentenoic acid (Δ 4 VPA), a metabolite of VPA, has been implicated in VPA-induced …

As a natural active substance, dihydromyricetin (DHM) has been proven to have good
hepatoprotective activity. However, the therapeutic effect of DHM on liver fibrosis, which has …

Liver disease is responsible for approximately 1.2 million global deaths per year, which
account for 3.5% of all deaths worldwide.[1] Acute liver injury is often reversible, while …

Chronic liver diseases, primarily metabolic dysfunction-associated steatotic liver disease
(MASLD), harmful use of alcohol, or viral hepatitis, may result in liver fibrosis, cirrhosis, and …

Heat stroke (HS) is a severe condition characterized by increased morbidity and high
mortality. Acute liver injury (ALI) is a well-documented complication of HS. The tumor …

Abstract Environmental aflatoxin B 1 (AFB 1) exposure has been proposed to contribute to
hepatocellular carcinoma by promoting liver fibrosis, but the potential mechanisms remain to …

The development of liver fibrosis is one of the most severe and life-threatening outcomes of
chronic liver disease (CLD). For targeted therapy of CLD, it is highly needed to reveal …

Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist,
has been used to treat metabolic diseases such as insulin resistance and diabetic …

Liver fibrosis, as a consequence of chronic liver disease, involves the activation of hepatic
stellate cell (HSC) caused by various chronic liver injuries. Emerging evidence suggests that …